These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22924417)

  • 1. Mechanistic insights into the antileukemic activity of hyperforin.
    Billard C; Merhi F; Bauvois B
    Curr Cancer Drug Targets; 2013 Jan; 13(1):1-10. PubMed ID: 22924417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperforin induces apoptosis of chronic lymphocytic leukemia cells through upregulation of the BH3-only protein Noxa.
    Zaher M; Tang R; Bombarda I; Merhi F; Bauvois B; Billard C
    Int J Oncol; 2012 Jan; 40(1):269-76. PubMed ID: 21947285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells.
    Merhi F; Tang R; Piedfer M; Mathieu J; Bombarda I; Zaher M; Kolb JP; Billard C; Bauvois B
    PLoS One; 2011; 6(10):e25963. PubMed ID: 21998731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BH3-only protein Noxa is stimulated during apoptosis of chronic lymphocytic leukemia cells triggered by M2YN, a new plant-derived extract.
    Zaher M; Mirshahi M; Nuraliev Y; Sharofova M; Bombarda I; Marie JP; Billard C
    Int J Oncol; 2011 Oct; 39(4):965-72. PubMed ID: 21750864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol.
    Zaher M; Akrout I; Mirshahi M; Kolb JP; Billard C
    Leukemia; 2009 Mar; 23(3):594-6. PubMed ID: 18784742
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperforin: more than an antidepressant bioactive compound?
    Medina MA; Martínez-Poveda B; Amores-Sánchez MI; Quesada AR
    Life Sci; 2006 Jun; 79(2):105-11. PubMed ID: 16438991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aqueous ethanolic extract of St. John's wort (Hypericum perforatum L.) induces growth inhibition and apoptosis in human malignant cells in vitro.
    Hostanska K; Reichling J; Bommer S; Weber M; Saller R
    Pharmazie; 2002 May; 57(5):323-31. PubMed ID: 12061257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia.
    Quiney C; Billard C; Faussat AM; Salanoubat C; Ensaf A; Naït-Si Y; Fourneron JD; Kolb JP
    Leukemia; 2006 Mar; 20(3):491-7. PubMed ID: 16424868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pro-apoptotic and anti-invasive effects of hypericin-mediated photodynamic therapy are enhanced by hyperforin or aristoforin in HT-29 colon adenocarcinoma cells.
    Šemeláková M; Mikeš J; Jendželovský R; Fedoročko P
    J Photochem Photobiol B; 2012 Dec; 117():115-25. PubMed ID: 23099482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
    Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
    Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells.
    Quiney C; Billard C; Faussat AM; Salanoubat C; Kolb JP
    Leuk Lymphoma; 2007 Aug; 48(8):1587-99. PubMed ID: 17701591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperforin acts as an angiogenesis inhibitor.
    Schempp CM; Kiss J; Kirkin V; Averbeck M; Simon-Haarhaus B; Kremer B; Termeer CC; Sleeman J; Simon JC
    Planta Med; 2005 Nov; 71(11):999-1004. PubMed ID: 16320199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperforin, a bio-active compound of St. John's Wort, is a new inhibitor of angiogenesis targeting several key steps of the process.
    Martínez-Poveda B; Quesada AR; Medina MA
    Int J Cancer; 2005 Dec; 117(5):775-80. PubMed ID: 15981212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic Apoptotic Pathways in Hepatocellular Carcinoma Cells.
    Chiang IT; Chen WT; Tseng CW; Chen YC; Kuo YC; Chen BJ; Weng MC; Lin HJ; Wang WS
    Anticancer Res; 2017 Jan; 37(1):161-167. PubMed ID: 28011486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells.
    Quiney C; Billard C; Mirshahi P; Fourneron JD; Kolb JP
    Leukemia; 2006 Apr; 20(4):583-9. PubMed ID: 16467866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperforin induces apoptosis through extrinsic/intrinsic pathways and inhibits EGFR/ERK/NF-κB-mediated anti-apoptotic potential in glioblastoma.
    Hsu FT; Chen WT; Wu CT; Chung JG
    Environ Toxicol; 2020 Oct; 35(10):1058-1069. PubMed ID: 32485087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperforin, a new lead compound against the progression of cancer and leukemia?
    Quiney C; Billard C; Salanoubat C; Fourneron JD; Kolb JP
    Leukemia; 2006 Sep; 20(9):1519-25. PubMed ID: 16791262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent.
    Gartner M; Müller T; Simon JC; Giannis A; Sleeman JP
    Chembiochem; 2005 Jan; 6(1):171-7. PubMed ID: 15593112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo.
    Rothley M; Schmid A; Thiele W; Schacht V; Plaumann D; Gartner M; Yektaoglu A; Bruyère F; Noël A; Giannis A; Sleeman JP
    Int J Cancer; 2009 Jul; 125(1):34-42. PubMed ID: 19326439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.